Axiom Intelligence Acquisition Corp 1 3Q 2026: Net income $1.36M — 10-Q Summary

Axiom Intelligence Acquisition Corp 1 reported a 28.6% YoY decline in net income to $1.36M for 3Q 2026, citing lower interest earned on Trust Account investments and higher expenses. The company has not started operations and expects no revenue until after a business combination. It has $166,607 in cash outside the Trust Account and a $1.09M working capital deficit, with management expressing doubt about its ability to continue as a going concern.

Original reporting
Published Nov 13, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Axiom Intelligence Acquisition Corp 1 3Q 2026: Net income $1.36M — 10-Q Summary — source image
Decision brief

The 30-second read

$AXINBearishLow
01

Why it matters

The filing reveals a net loss, a working‑capital deficit, and a going‑concern warning, all of which are new and material for investors.

02

Market read

The earnings decline and liquidity concerns are likely to depress AXIN's share price in the short term.

03

What to watch

Potential hidden cash in the trust account and any upcoming merger catalyst are not reflected in the current filing.

Relevance 6/10Novelty 6/10Timing: after‑hours filing

Background

Axiom Intelligence Acquisition Corp 1 (AXIN) is a SPAC that has not yet completed a business combination and filed its Q3 2026 10‑Q.

Company-level read

Ticker impact

$AXINBearishHigh confidence
Context

10-Q reports Q3 net income of $1.36M, a 28.6% YoY decline and a going‑concern warning.

Expected impact

likely pressure as investors price in the going‑concern risk and lack of operating revenue.

Evidence & confidence

Fresh earnings disclosure with a material decline and solvency doubts typically triggers sell‑side sentiment in micro‑caps.

Market effects

Highlights risk in the SPAC and blank‑check sector, potentially prompting caution among similar vehicles.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal; confined to niche SPAC investors.

Counterpoint

If the business combination with Terra Quantum proceeds, the stock could rebound despite current concerns.

Key entities

  • Axiom Intelligence Acquisition Corp 1

    SPAC awaiting merger with Terra Quantum.

  • Terra Quantum

    Proposed merger partner.

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.